Hematologic Malignancy Virtual Journal Club: Ofatumumab as Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia

Hematologic Malignancy Virtual Journal Club
Ofatumumab as Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia

Expert perspectives with Anders Österborg, MD, PhD

This independent medical education activity features an expert interview focusing on important data from the recent oncology literature in the field of hematologic malignancies.

Anders Österborg, MD, PhD, is interviewed regarding the published results of Hx-CD20-406, a study of ofatumumab in patients with chronic lymphocytic leukemia (CLL) refractory to both fludarabine and alemtuzumab treatment, or refractory to fludarabine and considered inappropriate for alemtuzumab treatment due to bulky lymphadenopathy and how these results may affect clinical practice.

Audience
The information on this site is intended for healthcare professionals based outside of the United States. You will be asked to provide your credentials before accessing the webcast and slides. This site may contain information on products outside the approved indications where you practice.

Support
This educational activity is supported by GlaxoSmithKline.

Click here
to view Webcast

Featured Experts

Speaker

Anders Österborg, MD, PhD
Karolinska University Hospital
Karolinska Institute
Stockholm, Sweden

Interviewer

Aristoteles Giagounidis, MD, PhD
St Johannes Hospital
Duisberg, Germany

Activity Date
This Webcast is available from 9 September 2010 to 9 September 2011.

Hematologic Malignancy Virtual Journal Club

Audience

Support

Featured Experts

Activity Date